HER2 testing in gastric and esophageal adenocarcinoma: New diagnostic challenges arising from new therapeutic options

Biotechnic and Histochemistry

Volumn 87, Issue 1, 2012, Pages 40-45

  Koltz, B R ^a   Hicks, D G ^a   Whitney Miller, C L ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Esophageal carcinoma; Gastric carcinoma; HER2; Transtuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; TRASTUZUMAB; TUMOR MARKER;

ADENOCARCINOMA; ARTICLE; CHEMISTRY; DRUG COMBINATION; ESOPHAGUS TUMOR; HUMAN; METABOLISM; PATHOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); STOMACH TUMOR;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG THERAPY, COMBINATION; ESOPHAGEAL NEOPLASMS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, ERBB-2; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 83755220469     PISSN: 10520295     EISSN: 14737760     Source Type: Journal    
DOI: 10.3109/10520295.2011.591830     Document Type: Article

References (32)

1. Akiyama T, Sudo G, Ogawara H, Toyoshima K, Yamamoto T (1986) The product of the human c-erbB-2 gene: A 185-kilo-Dalton glycoprotein with tyrosine kinase activity. Science 232: 1644-1646. (Pubitemid 16095607)
2. Alberts SR, Cervantes A, van de Valde CJH (2003) Gastric cancer: Epidemiology, pathology and treatment. Ann. Oncol. 14 (Suppl. 2): Ii31 - ii36. (Pubitemid 36874136)
3. Ali MA, Gunduz M, Gunduz E, Tamamura R, Beder LB, Katase N, Hatipoglu OF, Fukushima K, Yamanaki N, Shimizu K, Nagatsuka H (2010) Expression and mutation analysis of HER2 in head and neck squamous cell carcinoma. Cancer Invest. 28: 495-500.
4. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, R ü schoff J, Kang YK; ToGA Trial Investigators (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treat ment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 376: 687-697.
5. Barros-Silva JD, Leitão D, Afonso L, Vieira J, Dinis-Ribeiro M, Fragoso M, Bento MJ, Santos L, Ferreira P, Rěgo S, Brandão C, Carneiro F, Lopes C, Schmitt F, Teixeira MR. (2009) Association of ERBB2 gene status with histopathological parameters and disease-specifi c survival in gastric carcinoma patients. Br. J. Cancer 100: 487-493.
6. Bartsch R, Wenzel C, Steger GG (2007) Trastuzumab in the management of early and advanced stage breast cancer. Biologics 1: 19-31.
7. Grabsch H, Sivakumar S, Gray S, Gabbert HE, M ü ller W (2010) HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series. Cell Oncol. 32: 57-65.
8. Gravalos C, Jimeno A (2008) HER2 in gastric cancer: A new prognostic factor and a novel therapeutic target. Ann. Oncol 19: 1523-1529.
9. Gravalos C, Marquez A, Garcia-Carbonero R, Rivera F, Colomer R, Sastre J, Velasco A, Alonso V, Ales I, Gomez- Martin C (2007) Correlation between HER2/neu overexpression/amplifi cation and clinicopathological parameters in advanced gastric cancer patients: A prospective study. ASCO Gastrointestinal Cancers Symposium, Abstract 89.
10. Hicks DG, Kulkarni S (2008a) HER2 breast cancer: Review of biologic relevance and optimal use of diagnostic tools. Am. J. Clin. Pathol. 129: 263-273. (Pubitemid 352029317)
11. Hicks DG, Kulkarni S (2008b) Trastuzumab as adjuvant therapy for early breast cancer: The importance of accurate human epidermal growth factor receptor 2 testing. Arch. Pathol. Lab Med. 132: 1008-1015. (Pubitemid 351918709)
12. Hofmann M, Stoss O, Shi D, B ü ttner R, van de Vijver M, Kim W, Ochiai A, R ü schoff J, Henkel T. (2008) Assessment of a HER2 scoring system for gastric cancer: Results from a validation study. Histopathology 52: 797-805. (Pubitemid 351724903)
13. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics 2010. Ca Cancer J. Clin. 60: 277-300.
14. Kountourakis P, Pavlakis K, Psyrri A, Rontogianni D, Xiros N, Patsouris E, Pectasides D, Economopoulos T (2006) Clinicopathologic signifi cance of EGFR and Her-2/ neu in colorectal adenocarcinomas. Cancer J. 12: 229-236. (Pubitemid 43894340)
15. La é M, Couturier J, Oudard S, Radvanyi F, Beuzeboc P, Vieillefond A (2010) Assessing HER2 gene amplifi cation as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: Results in 1005 patients. Ann. Oncol. 21: 815-819.
16. Livasy CA, Reading FC, Moore DT, Boggess JF, Lininger RA (2006) EGFR expression and HER2/neu overexpression/ amplifi cation in endometrial carcinosarcoma. Gynecol. Oncol. 100: 101-106. (Pubitemid 41815057)
17. Lordick F, Bang YJ, Kang YK, Otero Reyes D, Manikhas GM, Shen L, Kulikov E, Stoss O, Jorden BWM, Van Cutsem E (2007) HER2-positive advanced gastric cancer: Similar HER2-positivity levels to breast cancer. Eur. J. Cancer Suppl. 5: 272, Poster #3541.
18. Madarnas Y, Trudeau M, Franek JA, McCready D, Pritchard KI, Messersmith H (2008) Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neuoverexpressing breast cancer: A systematic review. Cancer Treat. Rev. 34: 539-557.
19. Mezhir JJ, Tang LH, Coit DG (2010) Neoadjuvant therapy of locally advanced gastric cancer. J. Surg. Oncol 101: 305-314.
20. Nakajima M, Sawada H, Yamada Y, Watanabe A, Tatsumi M, Yamashita J, Matsuda M, Sakaguchi T, Hirao T, Nakano H (1999) The prognostic signifi cance of amplifi cation andoverexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 85: 1894-1902. (Pubitemid 29202761)
21. Oh DS, DeMeester SR (2010) Pathophysiology and treatment of Barrett ' s esophagus. World J. Gastroenterol 16: 3762-3772.
22. GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, Pignon JP, Rougier P, Sakamoto J, Sargent D, Sasako M, Van Cutsem E, Buyse M 2010 Benefi t of adjuvant chemotherapy for resectable gastric cancer: A meta-analysis. JAMA. 303 1729-1737.
23. Park DI, Yun JW, Park JH, Oh SJ, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI, Yoo CH, Son BH, Cho EY, Chae SW, Kim EJ, Sohn JH, Ryu SH, Sepulveda AR (2006) HER-2/ neu amplifi cation is an independent prognostic factor in gastric cancer. Dig. Dis. Sci 51: 1371-1379. (Pubitemid 44315804)
24. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics 2002. Ca Cancer J. Clin. 55: 74-108.
25. Pera M, Materola C, Vidal O, Grande L ( 2005) Epidemiology of esophageal adenocarcinoma. J. Surg. Oncol. 92: 151-159. (Pubitemid 41779297)
26. Pinto-de-Sousa J, David L, Almeida R, Leit ã o D, Preto JR, Seixas M, Pimenta A (2002) C-erb B-2 expression is associated with tumor location and venous invasion and infl uences survival of patients with gastric carcinoma. Int. J. Surg. Pathol. 10: 247-256. (Pubitemid 35461524)
27. Power DG, Kelsen DP, Shah MA (2010) Advanced gastric cancer - slow but steady progress. Cancer Treat. Rev 36: 384-392.
28. Rüschoff J, Dietel M, Baretton G, Arbogast S, Walch A, Monges G, Chenard MP, Penault-Llorca F, Nagelmeier I, Schlake W, Höfler H, Kreipe HH (2010) HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch. 457: 299-307.
29. Steffensen KD, Waldstr ø m M, Jeppesen U, Jakobsen E, Brandslund I, Jakobsen A (2007) The prognostic importance of cyclooxygenase 2 and HER2 expression in epithelial ovarian cancer. Int. J. Gynecol. Cancer. 17: 798-807. (Pubitemid 47063320)
30. Tanner M, Hollmen M, Junttila TT, Kapanen AI, Tommola S, Soini Y, Helin H, Salo J, Joensuu H, Sihvo E, Elenius K, Isola J (2005) Amplifi cation of HER-2 in gastric carcinoma: Association with topoisomerase II alpha gene amplifi cation, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann. Oncol. 16: 273-278. (Pubitemid 40309309)
31. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF; American Society of Clinical Oncology, College of American Pathologists (2007) American Society of Clinical Oncology/ College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 25: 118-145. (Pubitemid 350003059)
32. Yan B, Yau EX, Bte Omar SS, Ong CW, Pang B, Yeoh KG, Salto-Tellez M (2010) A study of HER2 gene amplifi - cation and protein expression in gastric cancer. J. Clin. Pathol 63: 839-842.